GLP-1 compound for weight loss
Patent Information
- Application Number
- MYPI2026002694
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-30
- Filing Date
- 2024-11-06
- Publication Date
- 2025-05-06
AI Technical Summary
The prior art is difficult to effectively treat obesity, especially patients with obesity-related health problems, and there are safety issues and the risk of weight loss drugs leading to weight recovery due to metabolic responses.
A GLP-1 derivative weight loss drug is provided, which is better than the existing semegglutide and Tirzepatide treatment effects by administering to a subject in need, with a weekly or biweekly dosing frequency and reducing the occurrence of obesity-related adverse events.
Achieve more effective weight loss, reduce the risk of obesity-related health problems, and reduce the metabolic response to weight recovery, providing a safe and effective auxiliary means to help patients maintain weight loss.
Abstract
Description
GLP-1 compounds for weight loss Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to a GLP-1 compound for treating obesity. Background Art
[0002] Obesity is a condition in which excessive accumulation of body fat leads to health problems. Over the past two decades, obesity has become a serious global medical and social problem. In a survey involving more than 192 million people, researchers analyzed global data trends from 1975 to 2014 and predicted that by 2025, the global obesity rate would be 18% for men and over 21% for women; of these, 6% of men and 9% of women would have a body mass index (BMI) exceeding 40 kg / m2. In China, a survey showed that 266 million adults were overweight and 53 million were obese, accounting for 27.8% and 5.5% of the total adult population, respectively (Yang Wenying, Lu Juming, Weng Jiangping, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med. 2010, 362(25): 2425-2426.).
[0003] In 2017, the World Obesity Federation defined obesity as a chronic, recurrent disease, believed to be the result of an interaction between genetic, metabolic, environmental, and behavioral factors. Obesity also increases morbidity and mortality. Obese individuals are more likely than healthy individuals to suffer from coronary heart disease, hypertension, hyperlipidemia, diabetes, cerebrovascular accidents, osteoarthritis, sleep apnea, and other conditions. Some studies have also shown an association between obesity and a higher incidence of certain cancers. Compared to normal-weight individuals of the same age, obese individuals have an increased risk of death from all causes.
[0004] Traditionally, lifestyle interventions in the form of dietary, behavioral, and exercise counseling have been the mainstay of treatment for obesity. However, the causes of obesity are multifactorial, linked to many complex environmental, physiological, and genetic factors, making its treatment challenging. Scientific evidence suggests that weight gain leads to hormonal, metabolic, and neurochemical adaptations that may affect the regulation of energy balance, promote the maintenance of weight gain, and make weight loss difficult. Furthermore, during periods of weight loss, the body appears to compensate by reducing metabolism and increasing the production of hormones that stimulate appetite. These combined effects often favor weight regain and explain why sustained weight loss is difficult to achieve and why many people struggle to maintain their weight with lifestyle interventions alone.
[0005] Surgical treatment offers an effective alternative for some patients with severe obesity. However, these options are unavailable or inappropriate for many obese patients and are often associated with risks and complications inherent to surgical procedures in obese patients. In one study, major and minor complication rates were 3.3% and 27%, respectively.
[0006] Therefore, few effective treatment options exist for patients with obesity, particularly those with obesity-related health problems. Pharmacological therapy can be a valuable adjunct to lifestyle interventions to achieve and maintain weight loss; it also has the potential to reduce metabolic responses that favor weight regain. However, the currently available weight loss medications are very limited.
[0007] Efforts to treat obesity with drugs have been plagued by safety issues, resulting in some drugs never being approved in the United States (rimonabant) or being withdrawn from the U.S. market after approval due to severe toxicity (fenfluramine, dexfenfluramine, phenylpropanolamine and sibutramine). In recent years, new drugs have been approved. To date, the drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic obesity are: orlistat, lorcaserin, phentermine, naltrexone, phentermine / topiramate, liraglutide, and semaglutide. Researchers have found that GLP-1 analogs or GLP-1 derivatives have the potential to reduce weight. The present invention provides a GLP-1 derivative weight-loss drug with excellent properties and a suitable dosage and frequency of administration.
[0008] Summary of the Invention
[0009] The present invention relates to a method for treating obesity, comprising administering a therapeutically effective amount of compound (I) to a subject in need thereof, wherein the subject has clinical evidence of obesity; wherein the therapeutic effect of the method is better than that of 2.4 mg of semaglutide injection and 15 mg of Tirzepatide, and can reduce the occurrence of obesity-related adverse events (MACE).
[0010] The present invention provides a method for treating or preventing obesity, comprising administering to a subject in need thereof about 0.25 mg to about 100 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof,
[0011] In some embodiments, wherein the method comprises administering to a subject in need thereof about 0.25-100 mg, preferably about 0.5-90 mg, preferably about 1-80 mg, preferably about 1.5-80 mg, preferably about 2-80 mg, preferably about 1.5-70 mg, preferably about 2-70 mg, preferably about 3-70 mg, preferably about 1.5-60 mg, preferably about 3-60 mg, preferably about 1.5-55 mg, preferably about 3-55 mg, preferably about 1.5-48 mg, preferably about 3-48 mg, preferably about 1.5-36 mg, preferably about 3-36 mg, preferably about 1.5-30 mg, preferably about 3-30 mg, preferably about 1.5-24 mg, preferably about 3-24 mg, preferably about 1.5-18 mg, preferably about 3-18 mg, preferably about 1.5-12 mg, Preferably, about 3-12 mg, preferably about 4-60 mg, preferably about 5-60 mg, preferably about 7-60 mg, preferably about 8-60 mg, preferably about 9-60 mg, preferably about 10-60 mg, preferably about 11-60 mg, preferably about 12-60 mg, preferably about 6-48 mg, preferably about 7-48 mg, preferably about 9-48 mg, preferably about 12-48 mg, preferably about 15-48 mg, preferably about 24-48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof.
[0012] In some embodiments, wherein the method comprises administering to a subject in need thereof about 0.25-100 mg, preferably about 0.5-90 mg, preferably about 1-80 mg, preferably about 1.5-80 mg, preferably about 2-80 mg, preferably about 1.5-70 mg, preferably about 2-70 mg, preferably about 3-70 mg, preferably about 3-60 mg, preferably about 1.5-55 mg, preferably about 3-55 mg, preferably about 1.5-48 mg, preferably about 3-48 mg, preferably about 1.5-36 mg, preferably about 3-36 mg, preferably about 1.5-30 mg, preferably about 3-30 mg, preferably about 1.5-24 mg, Preferably, the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered in a dose of about 3-24 mg, preferably about 1.5-18 mg, preferably about 3-18 mg, preferably about 1.5-12 mg, preferably about 3-12 mg, preferably about 4-60 mg, preferably about 5-60 mg, preferably about 7-60 mg, preferably about 8-60 mg, preferably about 9-60 mg, preferably about 10-60 mg, preferably about 11-60 mg, preferably about 12-60 mg, preferably about 6-48 mg, preferably about 7-48 mg, preferably about 9-48 mg, preferably about 12-48 mg, preferably about 15-48 mg, preferably about 24-48 mg.
[0013] In some embodiments, wherein the method comprises administering to a subject in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, weekly or biweekly at a dose of about 0.25 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg. or about 70 mg.
[0014] In some embodiments, the method comprises administering a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof once a week or less, preferably once every two weeks or less.
[0015] In some embodiments, wherein the method comprises administering to a subject in need thereof once a week or once every two weeks a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at a dose of about 0.25 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 or about 70 mg.
[0016] In some embodiments, the method comprises administering to a subject in need thereof an ascending dose at a frequency of once per week or once every two weeks during an ascending dose period, and then administering a maintenance dose at a frequency of once per week or once every two weeks during a maintenance dose period, wherein
[0017] The ascending dose period is at least two weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-31 weeks, preferably about 2-28 weeks, preferably about 2-30 weeks, preferably about 2-20 weeks, preferably the ascending dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks , about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks;
[0018] The maintenance dose period is at least about two weeks, preferably more than about 3 weeks, more than about 4 weeks, more than about 5 weeks, more than about 6 weeks, more than about 7 weeks, more than about 8 weeks, more than about 9 weeks, more than about 10 weeks, more than about 11 weeks, more than about 12 weeks, more than about 13 weeks, more than about 14 weeks, more than about 15 weeks, more than about 16 weeks, more than about 17 weeks, more than about 18 weeks, more than about 19 weeks, more than about 20 weeks, more than about 21 weeks, more than about 22 weeks, more than about 23 weeks, more than about 24 weeks, more than about 25 weeks, more than about 26 weeks, more than about 27 weeks, more than about 28 weeks, more than about 29 weeks, more than about 30 weeks, more than about 31 weeks, more than about 32 weeks, more than about 33 weeks, more than about 34 weeks, more than about 35 weeks, more than about 36 weeks, more than about 37 weeks , about 38 weeks or more, about 39 weeks or more, about 40 weeks or more, about 41 weeks or more, about 42 weeks or more, about 43 weeks or more, about 44 weeks or more, about 45 weeks or more, about 46 weeks or more, about 47 weeks or more, about 48 weeks or more, about 49 weeks or more, about 50 weeks or more, about 51 weeks or more, about 52 weeks or more, about 53 weeks or more, about 54 weeks or more, about 55 weeks or more, about 56 weeks or more, about 57 weeks or more, about 58 weeks or more, about 59 weeks or more, or about 60 weeks or more; preferably about 2-120 weeks, preferably about 2-100 weeks, preferably about 2-80 weeks, preferably about 2-70 weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-35 weeks, Preferably, the maintenance dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks;
[0019] The increasing dose is independently about 0.25 mg to 70 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration; preferably, the increasing dose is independently about 0.25 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 7.5 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg 67 mg, about 68 mg, about 69 mg, or about 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof;
[0020] The maintenance dose is about 3-70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; preferably, the maintenance dose is about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 7.5 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, or about 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and
[0021] The maintenance dose is greater than or equal to the escalating dose;
[0022] Preferably:
[0023] During the ascending dose period, the administration time of each different said ascending dose is each independently about 1 week or more, about 2 weeks or more, about 3 weeks or more, about 4 weeks or more, about 5 weeks or more, about 6 weeks or more, about 7 weeks or more, about 8 weeks or more, about 9 weeks or more, about 10 weeks or more, about 11 weeks or more, about 12 weeks or more, about 13 weeks or more, about 14 weeks or more, about 15 weeks or more, about 16 weeks or more, about 17 weeks or more, about 18 weeks or more, about 19 weeks or more, or about 20 weeks or more; preferably, during the ascending dose period, the administration time of each different said ascending dose is each independently about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, or about 20 weeks;
[0024] Preferably:
[0025] During the increasing dose period, the increasing dose is about 1.1-3 times, preferably about 1.1-2 times, preferably about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2.1 times, about 2.2 times, about 2.3 times, about 2.4 times, about 2.5 times, about 2.6 times, about 2.7 times, about 2.8 times, about 2.9 times or about 3 times the previous different increasing dose.
[0026] In some embodiments, the ascending dose period is about 8-31 weeks, preferably about 10-31 weeks, preferably the ascending dose period is about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 30 weeks or about 31 weeks; preferably the ascending dose period is about 10 weeks, about 14 weeks, about 18 weeks, about 28 weeks, or about 31 weeks;
[0027] The maintenance dose period is about 4 weeks or more, 5 weeks or more, about 12 weeks or more, about 14 weeks or more, about 16 weeks or more, about 18 weeks or more, or about 20 weeks or more; preferably, the maintenance dose period is about 4-20 weeks, preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, or about 20 weeks;
[0028] The increasing dose is independently about 1.5 mg, about 3 mg, about 5 mg, about 6 mg, about 7 mg, about 7.5 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration; preferably, the increasing dose is independently about 3 mg, about 6 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, about 24 mg, or about 36 mg of the compound of formula (I), at each administration. or a pharmaceutically acceptable salt, amide or ester thereof, or the increasing dose is independently about 1.5 mg, about 3 mg, about 5 mg, about 7 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, or about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration; or the increasing dose is independently about 3 mg, about 6 mg, about 9 mg, about 12 mg, about 18 mg, about 24 mg, about 36 mg or 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration;
[0029] The maintenance dose is about 5 mg, about 12 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and
[0030] The maintenance dose is greater than or equal to the incremental dose.
[0031] In some embodiments, the method comprises administering an ascending dose to a subject in need thereof at a frequency of once a week or once every two weeks during an ascending dose period, and then administering a maintenance dose at a frequency of once a week or once every two weeks during a maintenance dose period, wherein
[0032] The ascending dose period is about 10 weeks, about 14 weeks, about 18 weeks, about 28 weeks, about 30 weeks, or about 31 weeks;
[0033] The maintenance dose period is about 4 weeks or more, about 12 weeks or more, about 16 weeks or more, or about 20 weeks or more; preferably, the maintenance dose period is about 4 weeks, about 12 weeks, about 16 weeks, or about 20 weeks;
[0034] The increasing dose is independently about 1.5 mg, about 3 mg, about 5 mg, about 6 mg, about 7 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg or about 48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at each administration;
[0035] The maintenance dose is about 5 mg, about 12 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and
[0036] The maintenance dose is greater than or equal to the escalating dose;
[0037] Preferably:
[0038] When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof, sequentially, about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 or more weeks; about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 more weeks; about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 more weeks; and about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 20 or more weeks, preferably about 25 or more weeks, preferably about 30 or more weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0039] When the maintenance dose is about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more, about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more, about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 1 week or more, or about 1 week or more. or about 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once every two weeks for more than about 4 weeks; and about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once every two weeks for more than 16 weeks, preferably more than about 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0040] When the maintenance dose is about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more, about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more, about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more, about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 12 weeks or more, or about 12 mg of the compound of formula (I) once every two weeks for about 12 weeks or more. about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once every two weeks for about 4 weeks or more; about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once every two weeks for about 12 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0041] When the maintenance dose is about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more or about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 15 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 20 ... ), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0042] When the maintenance dose is about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more or about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 15 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 10 ... ), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0043] When the maintenance dose is about 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more or about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 12 weeks; administering about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 18 weeks; administering about 12 .... ), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; and about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0044] When the maintenance dose is about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 2 weeks or more or about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 12 ... about 15 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once a week for about 4 weeks or more; about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once a week for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or
[0045] When the maintenance dose is about 30 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 1 week or more; administering about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 2 weeks or more; administering about 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 4 weeks or more; administering about 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks. about 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once a week or once every two weeks for about 4 weeks or more; about 15 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once a week or once every two weeks for about 4 weeks or more; about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once a week or once every two weeks for about 4 weeks or more; ... About 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; and about 30 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, administered once a week or once every two weeks for about 4 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks.
[0046] In some embodiments, the method comprises administering to a subject in need thereof a first dose of about 0.25-5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0047] At least about 1 week after the first dose is administered, preferably about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks after, a second dose of about 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; preferably about 1, about 2, about 3 or about 4 weeks after the first dose is administered, a second dose of about 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks;
[0048] After administering the second dose for about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks, administering a third dose of about 6-24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof, once a week or once every two weeks; and
[0049] After about 3, about 4, about 5, about 6, about 7, or about 8 weeks of administration of the third dose, a fourth dose of about 9-36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks.
[0050] In some embodiments, after about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks of administration of the fourth dose, a fifth dose of about 12-48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
[0051] In some embodiments, after about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks of administration of the fifth dose, a sixth dose of about 18-60 mg of a compound of Formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
[0052] In some embodiments, after about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks of administration of the sixth dose, a seventh dose of about 24-72 mg of a compound of Formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; optionally, after about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks of administration of the seventh dose, an eighth dose of about 30-84 mg of a compound of Formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
[0053] In some embodiments, the first dose is about 0.5-5 mg, preferably about 1-4.5 mg, preferably about 1.5-4 mg, preferably about 1.5-3.5 mg, preferably about 2-3 mg, preferably about 3 mg;
[0054] In some embodiments, the second dose is about 3-7.5 mg, preferably about 3.5-7.5 mg, preferably about 4-7 mg, preferably about 4.5-6.5 mg, preferably about 5-6 mg, preferably about 6 mg;
[0055] In some embodiments, the third dose is about 5-24 mg, preferably about 6-20 mg, preferably about 6-18 mg, preferably about 6-12 mg, preferably about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, or about 20 mg, preferably about 9 mg or about 12 mg;
[0056] In some embodiments, the fourth dose is about 7-40 mg, preferably about 9-36 mg, preferably about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, or about 36 mg, preferably about 12 mg or about 24 mg;
[0057] In some embodiments, the fifth dose is about 9-50 mg, preferably about 12-48 mg, preferably about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg or about 48 mg, preferably about 15 mg, about 18 mg or about 36 mg;
[0058] In some embodiments, the sixth dose is about 12-50 mg, preferably about 18-60 mg, preferably about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, or about 60 mg, preferably about 24 mg or about 48 mg;
[0059] In some embodiments, the seventh dose is about 15-75 mg, preferably about 24-72 mg, preferably about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, or about 60 mg, preferably about 30 mg, about 36 mg or about 48 mg;
[0060] In some embodiments, the eighth dose is about 30-84 mg, preferably about 36-72 mg, preferably about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg. , about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, about 70 mg, about 71 mg or about 72 mg, preferably about 48 mg.
[0061] In some embodiments, wherein the method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0062] After administering the first dose for about 2 weeks or about 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0063] After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and
[0064] After administering the third dose for about 4 weeks, a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks. Preferably, a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for about 20 weeks.
[0065] In some embodiments, wherein the method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0066] After administering the first dose for about 2 or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0067] After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0068] After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0069] After administering the fourth dose for about 4 weeks, a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, the fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, the fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for about 16 weeks.
[0070] In some embodiments, wherein the method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0071] After administering the first dose for about 2 or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0072] After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0073] After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0074] After administering the fourth dose for about 4 weeks, administering a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0075] After administering the fifth dose for about 4 weeks, a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, the sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, the sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for about 12 weeks.
[0076] In some embodiments, wherein the method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0077] After administering the first dose for about 2 or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0078] After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0079] After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0080] After administering the fourth dose for about 4 weeks, administering a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0081] After administering the fifth dose for about 4 weeks, administering a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0082] After administering the sixth dose for about 4 weeks, administering a seventh dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks, preferably administering a seventh dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks for about 2 weeks or more, preferably about 4 weeks or more, preferably about 8 weeks or more, preferably about 12 weeks or more, preferably about 16 weeks or more, preferably about 20 weeks or more;
[0083] Preferably:
[0084] The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0085] After administering the first dose for about 2 or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0086] After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0087] After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0088] After administering the fourth dose for about 4 weeks, administering a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0089] After administering the fifth dose for about 4 weeks, administering a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0090] After administering the sixth dose for about 4 weeks, administering a seventh dose of about 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks;
[0091] After administering the seventh dose for about 4 weeks, an eighth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, an eighth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks.
[0092] In some embodiments, wherein the method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0093] After administering the first dose for about 2 or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0094] After administering the second dose for about 4 weeks, administering a third dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0095] After administering the third dose for about 4 weeks, administering a fourth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0096] After administering the fourth dose for about 4 weeks, administering a fifth dose of about 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0097] After administering the fifth dose for about 4 weeks, a sixth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, the sixth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, the sixth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 12 weeks.
[0098] In some embodiments, wherein the method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0099] After administering the first dose for about 2 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0100] After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0101] After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0102] After administering the fourth dose for 4 weeks, administering a fifth dose of about 15 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0103] After administering the fifth dose for about 4 weeks, a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 12 weeks.
[0104] In some embodiments, the method comprises administering to a subject in need thereof a first dose of about 0.25-3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or
[0105] After administering the first dose for about 1, about 2, about 3 or about 4 weeks, administering a second dose of about 1-5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or
[0106] After administering the second dose for about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks, administering a third dose of about 3-7 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof, once a week or once every two weeks; and / or
[0107] After administering the third dose for about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks, administering a fourth dose of about 5-9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or
[0108] administering the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks after administering the fourth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks; and / or administering the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks after administering the fifth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks; and / or administering the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks after administering the fifth dose for about 9-15 mg; and / or
[0109] administering the sixth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, followed by administering a seventh dose of about 12-18 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or
[0110] administering the seventh dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, and then administering an eighth dose of about 15-24 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or
[0111] administering the eighth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, and then administering a ninth dose of about 18-30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or
[0112] After administering the ninth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, a tenth dose of about 24-48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
[0113] In some embodiments, the first dose is about 0.5-3 mg, preferably about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, or about 3 mg, preferably about 1.5 mg;
[0114] In some embodiments, the second 'dose' is about 1-5 mg, preferably about 1 mg, about 2 mg, about 3 mg, about 4 mg, or about 5 mg, preferably about 3 mg;
[0115] In some embodiments, the third dose is about 3-7 mg, preferably about 3 mg, about 4 mg, about 5 mg, about 6 mg, or about 7 mg, preferably about 5 mg;
[0116] In some embodiments, the fourth dose is about 5-9 mg, preferably about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, preferably about 6 mg or about 7 mg;
[0117] In some embodiments, the fifth dose is about 7-12 mg, preferably about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, or about 12 mg, preferably about 9 mg;
[0118] In some embodiments, the sixth dose is about 9-15 mg, preferably about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg, preferably about 12 mg;
[0119] In some embodiments, the seventh dose is about 12-18 mg, preferably about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, or about 18 mg, preferably about 15 mg;
[0120] In some embodiments, the eighth dose is about 15-24 mg, preferably about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, or about 24 mg, preferably about 18 mg;
[0121] In some embodiments, the ninth dose is about 18-30 mg, preferably about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, preferably about 24 mg;
[0122] In some embodiments, the tenth dose is about 24-48 mg, preferably about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg or about 48 mg, preferably about 30 mg.
[0123] In some embodiments, the method comprises administering to a subject in need thereof a first dose of about 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;
[0124] After administering the first dose for about 1 week, administering a second dose of about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week;
[0125] After administering the second dose for about 2 weeks, administering a third dose of about 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week;
[0126] After administering the third dose for about 4 weeks, administering a fourth dose of about 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week;
[0127] After administering the fourth dose for about 4 weeks, administering a fifth dose of about 9 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0128] After administering the fifth dose for about 4 weeks, administering a sixth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0129] After administering the sixth dose for about 4 weeks, administering a seventh dose of about 15 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0130] After administering the seventh dose for about 4 weeks, administering an eighth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;
[0131] After administering the eighth dose for about 4 weeks, administering a ninth dose of about 24 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and
[0132] After administering the ninth dose for about 4 weeks, a tenth dose of about 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a tenth dose of about 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, a tenth dose of about 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for about 4 weeks.
[0133] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof, is administered parenterally, preferably subcutaneously.
[0134] In some embodiments, the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered for more than about 10 weeks, preferably more than about 15 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably more than about 35 weeks, preferably more than about 12 months, preferably more than about 16 months, preferably more than about 18 months, preferably more than about 24 months, preferably more than about 28 months, preferably more than about 29 months, preferably more than about 30 months.
[0135] In some embodiments, the aforementioned method is characterized in that the subject's BMI is ≥ 24 kg / m 2 , preferably BMI ≥ 25 kg / m 2 , preferably BMI ≥ 26 kg / m 2 ;
[0136] Preferred:
[0137] The subject also has at least one of the following symptoms:
[0138] 1) Patients with one or more of the following: prediabetes, hypertension, dyslipidemia, and fatty liver;
[0139] 2) combined with weight-bearing joint pain; and
[0140] 3) Obesity causing breathing difficulties or obstructive sleep apnea syndrome.
[0141] In some embodiments, in the aforementioned methods, the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof is administered in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients.
[0142] In some embodiments, the pharmaceutical composition comprises:
[0143] about 3 mg / ml, about 6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 24 mg / ml, about 36 mg / ml, or about 48 mg / ml of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof;
[0144] about 5 mg / ml, about 6 mg / ml, about 7 mg / ml, about 8 mg / ml, about 9 mg / ml, or about 10 mg / ml of NaCl, preferably about 7 mg / ml of NaCl;
[0145] about 1 mM, 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, 9 mM, or about 10 mM citric acid;
[0146] about 1.42 mg / ml, about 1.5 mg / ml, about 2 mg / ml, about 2.5 mg / ml, about 3 mg / ml, about 3.5 mg / ml, about 4 mg / ml, or about 4.5 mg / ml of a Na2HPO4 solution, preferably about 1.42 mg / ml of Na2HPO4; and
[0147] The pH of the pharmaceutical composition is about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, or about 8.2, preferably about 7.3.
[0148] In some embodiments, a subject is able to achieve a weight loss of about 5% or more, preferably about 10%-60%, preferably about 10%-50%, preferably about 10%-40%, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 10.16%, about 11%, about 11.15%, about 12%, about 12.23%, about 13%, about 13.22%, about 13.26%, about 13.5%, about 14%, about 14.25%, about 15%, about 16%, about 16.3%, about 16.79%, about 17%, about 17.29%, about 17.78%, about 18%, about 18.6%, about 19%, or about 20%. %; preferably, the subject can achieve a weight loss of about 10% or more, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 10.16%, about 11%, about 11.15%, about 12%, about 12.23%, about 13%, about 13.22%, about 13.26%, about 13.5%, about 14%, about 14.25%, about 15%, about 16%, about 16.3%, about 16.79%, about 17%, about 17.29%, about 17.78%, about 18%, about 18.6%, about 19%, or about 20% after about 10 weeks, about 20 weeks, about 25 weeks, about 30 weeks, or about 35 weeks of administration of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof.
[0149] In some embodiments, a subject is able to achieve a weight loss of about 10% or more, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 11%, about 12%, about 13%, about 13.5%, about 14%, about 15%, about 16%, about 17%, about 18%, about 18.6%, about 19%, or about 20% after administration of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof; preferably ... The compound, or a pharmaceutically acceptable salt, amide or ester thereof, can achieve a weight loss of more than about 10%, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 11%, about 12%, about 13%, about 13.5%, about 14%, about 15%, about 16%, about 17%, about 18%, about 18.6%, about 19%, or about 20% after about 10 weeks, about 20 weeks, about 25 weeks, about 30 weeks or about 35 weeks.
[0150] In some embodiments, when a fourth dose of about 12 mg of a compound of Formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 20 weeks, the average weight of the subjects is reduced by more than about 11.15% from baseline.
[0151] In some embodiments, when the fifth dose of about 18 mg of the compound of Formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 16 weeks, the average body weight of the subjects is reduced by more than about 13.22% from baseline.
[0152] In some embodiments, when a sixth dose of about 24 mg of a compound of Formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 12 weeks, the average weight of the subjects is reduced by more than about 14.25% from baseline.
[0153] In some embodiments, when the seventh dose of about 48 mg of the compound of Formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 8 weeks, the average body weight of the subjects is reduced by more than about 17.29% from baseline.
[0154] In some embodiments, when a sixth dose of about 24 mg of a compound of Formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once weekly for more than about 12 weeks, the average weight of the subjects is reduced by more than about 17.78% from baseline.
[0155] definition
[0156] For a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0157] GLP-1 analogs and GLP-1 derivatives
[0158] As used herein, the term "GLP-1 analog" or "GLP-1 analog" refers to a peptide or compound that is a variant of human glucagon-like peptide-1 (GLP-1(7-37)), wherein one or more amino acid residues of GLP-1(7-37) are replaced, and / or one or more amino acid residues are deleted, and / or one or more amino acid residues are added. Specifically, the sequence of GLP-1(7-37) is shown in SEQ ID NO: 1 in the sequence listing. The peptide having the sequence shown in SEQ ID NO: 1 may also be referred to as "native" GLP-1 or "native" GLP-1(7-37).
[0159] In the sequence listing, the first amino acid residue (histidine) of SEQ ID NO: 1 is numbered 1. However, hereinafter, in accordance with established conventions in the art, the histidine residue is numbered 7, and subsequent amino acid residues are numbered accordingly, ending with glycine at position 37. Therefore, generally, the amino acid residue numbering or position numbering of the GLP-1 (7-37) sequence referred to herein is a sequence starting with His at position 7 and ending with Gly at position 37.
[0160] The [Gly8, Arg34]GLP-1-(7-37) peptide is a GLP-1 analog having Gly and Arg at positions corresponding to position 8 and position 34 of GLP-1(7-37) (SEQ ID NO: 1), respectively. The [Arg34]GLP-1-(7-37) peptide is a GLP-1 analog having Arg at a position corresponding to position 34 of GLP-1(7-37) (SEQ ID NO: 1). Specifically, the amino acid sequence of the [Gly8, Arg34]GLP-1-(7-37) peptide is shown in SEQ ID NO: 2 in the sequence listing.
[0161] In the context of a GLP-1 peptide or analog thereof, the term "derivative" as used herein refers to a chemically modified GLP-1 peptide or analog wherein one or more substituents have been covalently attached to the peptide. Substituents may also be referred to as side chains.
[0162] Unless otherwise stated, when reference is made to acylation with a lysine residue, this is understood to be to be carried out with the e-amino group thereof.
[0163] The term "peptide" when applied to, for example, the GLP-1 analogs of the present invention, refers to a compound comprising a series of amino acids interconnected by amide (or peptide) bonds.
[0164] In a specific embodiment, the peptide is largely or predominantly composed of amino acids linked to each other by amide bonds (e.g., at least 50%, 60%, 70%, 80%, or at least 90% by molar mass). In another specific embodiment, the peptide is composed of amino acids linked to each other by peptide bonds.
[0165] Amino acids are molecules containing an amino group and a carboxylic acid group, optionally with one or more additional groups, often called side chains.
[0166] The term "amino acid" includes proteinogenic amino acids (encoded by the genetic code, including natural amino acids and standard amino acids), as well as non-proteinogenic (not found in proteins and / or not encoded in the standard genetic code), and synthetic amino acids. Non-proteinogenic amino acids are moieties that can be incorporated into peptides via peptide bonds, but are not proteinogenic amino acids. Synthetic non-proteinogenic amino acids include amino acids produced by chemical synthesis, i.e., D-isomers of amino acids encoded by the genetic code, such as D-alanine and D-leucine, Aib (α-aminoisobutyric acid), Abu (α-aminobutyric acid), 3-aminomethylbenzoic acid, anthranilic acid, desamino-histidine, β-analogs of amino acids such as β-alanine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, and homohistidine, etc.
[0167] Non-limiting examples of amino acids not encoded by the genetic code are γ-carboxyglutamate, ornithine, D-alanine, D-glutamine and phosphoserine. Non-limiting examples of synthetic amino acids are the D-isomers of amino acids, such as D-alanine and D-leucine, Aib (α-aminoisobutyric acid), β-alanine and des-amino-histidine (desH, alternative name imidazole propionic acid, abbreviated Imp).
[0168] In the following, all amino acids not indicating the optical isomer are understood to refer to the L-isomer (unless otherwise specified).
[0169] As used herein, the terms "about" or "approximately" when referring to a specifically recited value or range of values generally mean within 20%, preferably within 10%, and more preferably within 5% of the given value or range.
[0170] The term "treatment" includes therapeutic treatment, prophylactic treatment, and use in reducing the risk of a subject developing a disease or other risk factors. Treatment includes, but is not limited to, complete cure of the disease, as well as alleviation of symptoms or mitigation of potential risks. DETAILED DESCRIPTION
[0171] The embodiments of the present invention will be described in detail below with reference to the examples, but those skilled in the art will appreciate that the following examples are intended only to illustrate the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.
[0172] Abbreviations AE: adverse event AESI: adverse event of special interest AUC: area under the drug concentration-time curve HbA1c: glycosylated hemoglobin GLP-1: glucagon-like peptide-1 BMI: body mass index N: number of subjects
[0173] Example 1
[0174] Preparation of the title compound: N-ε 26 -[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide (Compound (I))
[0175] Compound I is a GLP-1 receptor agonist with CAS registration number: 2668298-70-0, and can be prepared by referring to the method described in, for example, WO2021136303A1.
[0176] Example 2 Pharmaceutical composition of compound (I)
[0177] Preparation of pharmaceutical composition 1 of compound (I): different concentrations of compound (I)_(15mg / 3ml / or 90mg / 3ml), 14mg / ml propylene glycol, 1.42mg / ml anhydrous disodium hydrogen phosphate, pH 7.3.
[0178] Pharmaceutical composition 2 of compound (I) was prepared: different concentrations of compound (I) (15 mg / 3 ml or 90 mg / 3 ml), 14 mg / ml propylene glycol, 1.42 mg / ml anhydrous disodium hydrogen phosphate, and about 5 mM citric acid; pH was 7.3.
[0179] Pharmaceutical composition 3 of compound (I) was prepared: different concentrations of compound (I) (15 mg / 3 ml or 90 mg / 3 ml), 8.25 mg / ml (141.17 mM) sodium chloride, 1.42 mg / ml anhydrous disodium hydrogen phosphate, and about 5 mM citric acid; pH was 7.3.
[0180] Example 3 Weight Loss Effect of Compound (I) Injection
[0181] A multicenter, randomized, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of Compound (I) injection in obese / overweight adult subjects in China. The main purpose of this Phase II clinical study is to evaluate the weight loss effect of Compound (I) injection in obese / overweight adult subjects.
[0182] Test drug, dosage and administration method, batch number:
[0183] Drug name: Compound (I) injection;
[0184] Specifications: 3mL / vial (5mg / mL or 30mg / mL);
[0185] Batch number: P3AI122001 / P3AI423001;
[0186] Valid until: October 2024 / April 2025;
[0187] Dosage: Subcutaneous injection (equilibrate to room temperature before injection);
[0188] Produced and provided by Gan & Lee Pharmaceutical Co., Ltd.
[0189] Comparative drug, dosage and administration method, batch number:
[0190] Drug name: Placebo;
[0191] Specifications: 3mL / tube (excluding compound (I));
[0192] Batch number: P3AIM21003 / P3AI4M23001;
[0193] Valid until: August 2026 / April 2028;
[0194] Dosage: Subcutaneous injection (equilibrate to room temperature before injection);
[0195] Produced and provided by Gan & Lee Pharmaceutical Co., Ltd.
[0196] Research Methodology:
[0197] This study is a multicenter, randomized, placebo-controlled Phase II clinical study conducted in Chinese adult obese / overweight subjects to evaluate the efficacy of Compound (I) injection in these subjects. The trial included adult obese / overweight subjects whose weight was not adequately controlled by diet and exercise.
[0198] Eligible subjects were screened and assigned to five different treatment groups: four groups receiving subcutaneous injections of Compound (I) (or corresponding volumes of placebo) at target or maintenance doses (12 mg, 18 mg, 24 mg, and 48 mg) every two weeks, and one group receiving subcutaneous injections of Compound (I) (or corresponding volumes of placebo) at a target dose (24 mg*) every week. All subjects received standard diet and exercise guidance after randomization.
[0199] Each subject will be followed for up to 34 weeks, including a 1-week screening period, a 30-week dosing treatment period / study visits (10-18 weeks of dose adjustment and 12-20 weeks of stable dose treatment), and a 3-week safety follow-up period.
[0200] The placebo is a Compound (I) solvent excipient, does not contain Compound (I), and the remaining ingredients are similar to those of the Compound (I) injection. The appearance, weight, and odor of the placebo are similar to those of the test drug. It is produced and provided by Ganli Pharmaceutical Co., Ltd.
[0201] As shown in Table 1, the subjects were randomized and administered Compound (I) injection or the same volume of placebo according to the dosing regimen in Table 1.
[0202] Table 1 Dosage regimen Note: W stands for week, and W2 / 4 means the second or fourth week.
[0203] Compound (I) - 24 mg (or 18 mg) ※ It indicates that the subjects in the previous dosing regimen of 18 mg once a week group do not agree to enter the 24 mg once a week dosing group and will continue to be administered with the 18 mg dose from W18 to W29.
[0204] Table 2. Subject inclusion and exclusion criteria (eligible subjects should meet all inclusion criteria; for subjects to be excluded, they meet one or more exclusion criteria)
[0205] Statistical methods:
[0206] Analysis Set
[0207] FAS: Includes all randomized subjects who received at least one dose of the investigational drug. This dataset serves as the primary analysis set for demographic data, baseline parameters, medical history, and efficacy.
[0208] PPS: A subset of FAS, consisting of subjects who met all inclusion criteria, did not meet exclusion criteria, had a primary endpoint efficacy measure, and had no other major protocol deviations. This dataset was used for supportive analysis of the primary efficacy.
[0209] SS: includes all randomized subjects who received at least one trial drug and had at least one safety evaluation. This dataset is used for statistical analysis of safety indicators.
[0210] PKCS: Includes all subjects who were randomized, received at least one dose of the study drug, and had at least one available blood concentration after the dose.
[0211] mPKCS: A subset of PKCS that includes all subjects who were randomized, received at least one dose of the study drug, underwent a dense blood draw, and had at least one available dense blood draw drug concentration.
[0212] PKPS: includes all subjects who were randomized, received at least one dose of the investigational drug, and had at least one valid PK parameter data after the dose.
[0213] mPKPS: A subset of PKPS that includes all subjects who were randomized, received at least one dose of investigational product, underwent intensive blood sampling, and had at least one valid intensive blood sampling PK parameter data.
[0214] General approach
[0215] Regarding the GZR18 48 mg dose group administered every two weeks, based on actual clinical trial results, some subjects maintained a stable dose of 36 mg, failing to reach the 48 mg dose. Therefore, this dose group was split into the "GZR18 36 mg dose group every two weeks," the "GZR18 48 mg dose group every two weeks," and the "other dose groups." Additional statistical analysis was conducted with the placebo combined from all dose groups to further explore the efficacy of the GZR18 36 mg dose group administered every two weeks. Efficacy indicators analyzed included weight, BMI, waist circumference, hip circumference, and waist-to-hip ratio. The splitting rule was: if the W28 dose was 48 mg, it was classified as the "GZR18 48 mg dose group every two weeks," if the W28 dose was 36 mg, it was classified as the "GZR18 36 mg dose group every two weeks," and if W28 was administered at doses other than 48 mg or 36 mg, or if no medication was administered, it was classified as the "other dose group."
[0216] Effectiveness Analysis
[0217] Main estimation target analysis
[0218] Based on FAS, Proc MI in SAS was used to fill in missing weight data based on the fully conditional definition method (FCS).
[0219] Main analysis model: Based on FAS, covariance analysis (ANCOVA) was performed on the percentage change in W30 body weight from baseline, with the percentage change in body weight from baseline as the dependent variable, baseline as the covariate, and group as the fixed effect (in the model of GZR18 24 mg (or 18 mg) once a week vs. placebo and the model of GZR18 48 mg (or 36 mg) once every two weeks vs. placebo, compliance with planned dosing during the stable period was additionally added as a covariate). The least squares mean of the percentage change from baseline in each treatment group and its two-sided 95% confidence interval (CI) and the least squares mean between-group difference (GZR18-placebo) and its two-sided 95% CI were calculated.
[0220] The analysis results after imputation were combined and summarized based on Proc MIANALYZE in SAS. If the upper limit of the two-sided 95% CI confidence interval of the combined least squares mean between-group difference (GZR18-placebo) was less than 0, and the one-sided P value of the between-group comparison was less than 0.025, it indicated that GZR18 was superior to placebo.
[0221] Secondary Estimation Target Analysis
[0222] Continuous variables
[0223] Primary analysis method: Based on the FAS, multiple imputation was used to fill missing data. The imputed data were analyzed using the same analysis method as the primary analysis method for the main estimation target, and finally the analysis results of all visits were combined.
[0224] Binary variables
[0225] 1) The proportion of subjects whose weight decreased by ≥5%, 10%, 15%, 20%, and 25% compared with baseline at each visit.
[0226] Main analysis method: The missing data of each visit were filled using the same imputation method as the primary analysis method for the secondary estimation target of the change in weight at each visit compared with the baseline, and dichotomous variables were derived. The imputed data were statistically analyzed using a generalized linear model (partially using a logistic regression model). In the model, baseline weight was a covariate and group was a fixed effect. The rate difference between groups and the two-sided 95% CI were calculated.
[0227] 2) Proportion of subjects whose W30 weight increased by ≥5% compared to baseline
[0228] Main analysis method: Based on FAS, the missing data of W30 were imputed using the imputation method consistent with the main analysis method in the main estimation objective, and dichotomous variables were derived. The imputed data were statistically analyzed using a generalized linear model (partially using a logistic regression model). In the model, baseline weight was a covariate and group was a fixed effect. The between-group rate difference and two-sided 95% CI were calculated.
[0229] Research Results:
[0230] 1. Distribution of subjects
[0231] A total of 465 subjects were screened in this study, of whom 340 (73.1%) were successfully screened and 125 (26.9%) failed the screening. The reasons for screening failure were "not meeting the inclusion criteria / meeting the exclusion criteria" in 121 (26.0%) cases, "subjects withdrew informed consent" in 2 (0.4%) cases, and "others" in 2 (0.4%) cases.
[0232] A total of 340 subjects were randomly enrolled in this study, including 52 subjects in the Compound (I) 12 mg (once every 2 weeks) group, 53 subjects in the Compound (I) 18 mg (once every 2 weeks) group, 52 subjects in the Compound (I) 24 mg (once every 2 weeks) group, 64 subjects in the Compound (I) 48 mg (once every 2 weeks) group, 53 subjects in the Compound (I) 24 mg (18 mg) (once every week) group, and 66 subjects in the placebo group. Of all the randomized subjects, 340 subjects (100.0%) received the trial drug.
[0233] A total of 286 subjects (84.1%) completed the trial in this study, including 44 subjects (84.6%) in the Compound (I) 12 mg (once every 2 weeks) group, 49 subjects (92.5%) in the Compound (I) 18 mg (once every 2 weeks) group, 45 subjects (86.5%) in the Compound (I) 24 mg (once every 2 weeks) group, 46 subjects (71.9%) in the Compound (I) 48 mg (once every 2 weeks) group, 45 subjects (84.9%) in the Compound (I) 24 mg (18 mg) (once every week) group, and 57 subjects (86.4%) in the placebo group.
[0234] 2. Demographics and baseline characteristics
[0235] A total of 340 subjects were included in this study. The mean ± standard deviation (SD) age of the subjects was 33.1 ± 7.23 years. There were 185 (54.4%) males and 155 (45.6%) females. 326 (95.9%) were Han Chinese, and 14 (4.1%) were other ethnic groups. The mean ± SD height was 169.00 ± 9.418 cm; the mean ± SD weight was 95.63 ± 19.712 kg; and the mean ± SD BMI was 33.24 ± 4.621 kg / m 2 313 cases (92.1%) were obese (≥ 28 kg / m 2 ), 27 cases (7.9%) were overweight (≥24 and <28 kg / m 2 ); the average waist circumference ± SD was 106.81 ± 12.541 cm; the average hip circumference ± SD was 112.33 ± 9.335 cm; the average waist-to-hip ratio ± SD was 0.95 ± 0.074.
[0236] The demographic and baseline characteristics of the subjects in each group were basically balanced and comparable.
[0237] 3. Medication compliance:
[0238] In this study, 332 subjects (97.6%) had a medication compliance rate between 80% and 120%, and 8 subjects (2.4%) had a medication compliance rate less than 80%.
[0239] In this study, 300 subjects (88.2%) had a planned medication compliance between 80% and 120%, and 40 subjects (11.8%) had a planned medication compliance of less than 80%.
[0240] A total of 340 subjects (100.0%) were included in the full analysis set (FAS) and safety data set (SS), 274 subjects (80.6%) were included in the per-protocol set (PPS), 250 subjects (73.5%) were included in the pharmacokinetic concentration set (PKCS), and 79 subjects (23.2%) were included in the densely sampled pharmacokinetic concentration set (mPKCS), pharmacokinetic parameter set (PKPS), and densely sampled pharmacokinetic parameter set (mPKPS).
[0241] Overweight or obese subjects received subcutaneous injections of Compound (I) at four different target doses (12 mg, 18 mg, 24 mg, and 48 mg) every two weeks, and at one target dose (18 mg / 24 mg) every week for 30 weeks. The results showed that Compound (I) injection effectively reduced the weight of overweight or obese subjects and showed a trend toward lowering waist circumference, blood sugar, blood lipids, blood pressure, uric acid, and other metabolic indicators, including liver enzymes.
[0242] 4. Efficacy results:
[0243] Weight change indicators
[0244] The primary efficacy endpoint of this study is the percentage change in body weight compared to baseline at week 30 (W30). The primary endpoint, percentage change in body weight compared to baseline at W30, was tested using a fixed sequence test method. The test sequence is as follows:
[0245] 1) Compound (I)-48 mg once every two weeks vs. placebo
[0246] 2) Compound (I)-24 mg (or 18 mg) once a week vs placebo
[0247] 3) Compound (I)-24 mg once every two weeks vs. placebo
[0248] 4) Compound (I)-18 mg once every two weeks vs. placebo
[0249] 5) Compound (I)-12 mg once every two weeks vs placebo
[0250] The test level was one-sided α = 0.025. When the P value of the first dose group test was < 0.025, it was considered statistically significant and the next dose group test was performed. When the P value of a dose group was ≥ 0.025, the subsequent dose group test was stopped. The main analysis method was based on FAS. Each dose group was multiply imputed based on the population with no missing W30 in the combined placebo group. The placebo group was multiply imputed based on itself. The imputed variables included baseline weight, W30 weight, baseline BMI range (obesity: BMI ≥ 28 kg / m 2 , overweight: 24kg / m 2 ≤BMI<28kg / m 2 ),gender.
[0251] Table 3: Summary of change in body weight from baseline at W30 (kg) (Primary analysis method: LR MI1 (FAS))
[0252] The results showed that the least square mean differences in body weight changes compared with baseline in the Compound (I) 48 mg (once every 2 weeks) group, the Compound (I) 24 mg (or 18 mg) (once every week) group, the Compound (I) 24 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 12 mg (once every 2 weeks) group and the placebo group were -14.83 kg [95% CI: (-17.84, -11.81)], -15.82 kg [95% CI: (-18.48, -13.16)], -11.09 kg [95% CI: (-13.72, -8.47)], -10.70 kg [95% CI: (-13.71, -10.71)], and -12.97 kg [95% CI: (-13.70, -10.71)], respectively. %CI: (-13.15, -8.24)], -7.91 kg [95%CI: (-10.43, -5.40)]; the least squares mean differences in percentage changes from baseline between the groups were -15.51% [95%CI: (-18.62%, -12.39%)], -16.69% [95%CI: (-19.48%, -13.90%)], -11.79% [95%CI: (-14.61%, -8.96%)], -11.43% [95%CI: (-14.17%, -8.69%)], and -8.46% [95%CI: (-11.19%, -5.72%)]. According to the above-mentioned sequential tests, the one-sided P values for the inter-group differences between each dose group and placebo were all <0.001, and the percentage change in W30 body weight compared with baseline in each dose group was superior to that of placebo.
[0253] Proportion of subjects with a weight loss of ≥5%, 10%, 15%, 20%, 25% from baseline
[0254] The primary analysis was based on the FAS, using a placebo group model and multiple imputation. A logistic regression model was used to calculate the 95% confidence interval (CI) for each group and the adjusted rate difference between groups. Bootstrap methods were used to calculate the standard error and 95% CI for the rate difference. Percentages are presented in Table 4 after using a logistic regression model with multiple imputation and a summary analysis using Rubin's formula.
[0255] Table 4 Proportions of subjects with a W30 weight loss of ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% compared to baseline Primary analysis method: LR MI1 (FAS)
[0256] Conclusion: As can be seen from Table 4, the proportions of subjects whose W30 body weight decreased by ≥5% compared with baseline were 71.8%, 86.4%, 88.5%, 93.9%, 91.0% and 18.4% in the Compound (I) 12 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 24 mg (18 mg) (once every week) group, and the placebo group, respectively. The differences in proportions between each group and the placebo group were 54.5% [95% CI: (38.5%, 70.5%)], 67.9% [95% CI: (54.3%, 81.5%)], 73.7% [95% CI: (62.1%, 85.4%)], 78.5% [95% CI: (68.1%, 88.9%)], and 73.5% [95% CI: (61.0%, 86.0%)], respectively.
[0257] The proportions of subjects whose W30 body weight decreased by ≥10% compared with baseline were 48.7%, 61.0%, 72.1%, 77.4%, 85.5% and 6.7% in the Compound (I) 12 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 24 mg (18 mg) (once every week) group and the placebo group, respectively. The differences in proportions between each group and the placebo group were 38.7% [95% CI: (25.8%, 51.6%)], 54.1% [95% CI: (40.7%, 67.5%)], 63.6% [95% CI: (48.1%, 79.0%)], 70.3% [95% CI: (57.5%, 83.0%)], and 76.9% [95% CI: (64.6%, 89.2%)], respectively.
[0258] The proportions of subjects whose W30 body weight decreased by ≥15% compared with baseline were 23.8%, 35.5%, 40.9%, 55.1%, 61.0% and 4.0% in the Compound (I) 12 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 24 mg (18 mg) (once every week) group, and the placebo group, respectively. The differences in proportions between each group and the placebo group were 18.6% [95% CI: (6.0%, 31.2%)], 31.0% [95% CI: (18.6%, 43.3%)], 36.1% [95% CI: (20.6%, 51.7%)], 51.5% [95% CI: (37.5%, 65.5%)], and 57.3% [95% CI: (44.0%, 70.6%)], respectively.
[0259] The proportions of subjects whose W30 body weight decreased by ≥20% compared with baseline were 7.9%, 16.6%, 18.6%, 32.1%, 36.0% and 3.3% in the Compound (I) 12 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 24 mg (18 mg) (once every week) group, and the placebo group, respectively. The differences in proportions between each group and the placebo group were 4.7% [95% CI: (-5.6%, 15.0%)], 13.6% [95% CI: (3.9%, 23.3%)], 14.8% [95% CI: (4.0%, 25.6%)], 28.0% [95% CI: (15.5%, 40.5%)], and 32.4% [95% CI: (18.3%, 46.6%)], respectively.
[0260] The proportions of subjects whose W30 body weight decreased by ≥25% compared with baseline were 3.9%, 1.9%, 2.0%, 7.4%, 10.1% and 1.6% in the Compound (I) 12 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 24 mg (18 mg) (once every week) group, and the placebo group, respectively. The differences in proportions between each group and the placebo group were 2.3% [95% CI: (-4.3%, 9.0%)], 0.3% [95% CI: (-4.2%, 4.9%)], 0.6% [95% CI: (-5.2%, 6.3%)], 4.7% [95% CI: (-2.5%, 11.9%)], and 8.1% [95% CI: (-1.0%, 17.2%)], respectively.
[0261] The weight loss values of each dose group of Compound (I) compared with the baseline were statistically significant compared with the placebo group, indicating that the weight loss efficacy of each dose group of Compound (I) was better than that of the placebo group.
[0262] In the Compound (I) once every 2 weeks group, the proportion of subjects whose body weight decreased by ≥5%, 10%, 15%, and 20% compared with baseline increased with increasing doses.
[0263] Change from baseline in BMI
[0264] The primary analysis method was based on the FAS. Missing data were imputed using multiple imputation based on the missing-at-random (MAR) assumption. LSMean was based on a covariance model, with the dependent variable being the change from baseline or the percentage change from baseline, the baseline value as a covariate, and group as a fixed effect.
[0265] W30 Summary of changes in BMI compared to baseline (kg / m 2 )-Main analysis method: ANCOVA MI (FAS) See Table 5 for details.
[0266] Table 5 Summary of changes in BMI compared to baseline at W30 (kg / m 2 ) Main analysis method: ANCOVA MI (FAS)
[0267] According to the above data, the least square mean differences of the changes in BMI at W30 compared with the baseline in the Compound (I) 12 mg (once every 2 weeks) group, the Compound (I) 18 mg (once every 2 weeks) group, the Compound (I) 24 mg (once every 2 weeks) group, the Compound (I) 48 mg (once every 2 weeks) group, the Compound (I) 24 mg (18 mg) (once every week) group and the placebo group were -3.07 kg / m 2[95% CI: (-3.93, -2.20)], -3.86 kg / m 2 [95% CI: (-4.71, -3.01)], -4.24kg / m 2 [95% CI: (-5.10, -3.38)], -5.46kg / m 2 [95% CI: (-6.32, -4.60)], -5.36kg / m 2 [95% CI: (-6.21, -4.52)].
[0268] In FAS and PPS, the magnitude of decrease in BMI at W30 compared with baseline in all dose groups of Compound (I) was greater than that in the placebo group. The magnitude of decrease in BMI in the Compound (I) twice-weekly group increased with increasing dose. The results of various analytical methods were consistent.
[0269] Change in hip circumference from baseline
[0270] The primary analysis was based on the FAS. Missing data were imputed using multiple imputation based on the MAR assumption. LSMean was based on a covariance model, with the dependent variable being the change from baseline or the percentage change from baseline, the baseline value as a covariate, and group as a fixed effect.
[0271] Summary of changes in W30 hip circumference from baseline (cm) - Primary analysis method: ANCOVA MI (FAS) See Table 6 for details.
[0272] Table 6 Summary of changes in hip circumference from baseline at W30 (cm) Primary analysis method: ANCOVA MI (FAS)
[0273] Conclusion: The least square mean differences in the changes in W30 hip circumference compared with baseline in the compound (I) 12 mg (once every 2 weeks) group, compound (I) 18 mg (once every 2 weeks) group, compound (I) 24 mg (once every 2 weeks) group, compound (I) 48 mg (once every 2 weeks) group, compound (I) 24 mg (18 mg) (once every week) group and placebo group were -5.35 cm [95% CI: (-7.20, -3.50)], -6.51 cm [95% CI: (-8.30, -4.72)], -6.84 cm [95% CI: (-8.67, -5.00)], -9.90 cm [95% CI: (-11.75, -8.05)], and -9.12 cm [95% CI: (-10.97, -7.27)], respectively.
[0274] In FAS and PPS, the decrease in hip circumference at W30 compared with baseline in all dose groups of Compound (I) was greater than that in the placebo group. The decrease in hip circumference in the Compound (I) once every 2 weeks group increased with increasing dose. The results of various analytical methods were consistent.
[0275] Change in HbA1c from baseline
[0276] The primary analysis was based on the FAS. Missing data were imputed using multiple imputation based on the MAR assumption. LSMean was based on a covariance model, with the dependent variable being the change from baseline or the percentage change from baseline, the baseline value as a covariate, and group as a fixed effect.
[0277] Summary of W30 HbA1c change from baseline (%) - Primary analysis method: ANCOVA MI (FAS) See Table 7 for details.
[0278] Table 7 Summary of changes in W30 HbA1c from baseline (%) Primary analysis method: ANCOVA MI (FAS)
[0279] Conclusion: The compound (I) 12 mg (once every 2 weeks) group, the compound (I) 18 mg (once every 2 weeks) group, the compound (I) 24 mg (once every 2 weeks) group, the compound (I) 48 mg (once every 2 weeks) group, the compound (I) 24 mg (18 mg) (once every week) group and the placebo group W30 The least square mean differences in HbA1c changes from baseline between the groups were -0.352% [95% CI: (-0.466%, -0.239%)], -0.346% [95% CI: (-0.459%, -0.233%)], -0.400% [95% CI: (-0.520%, -0.280%)], -0.515% [95% CI: (-0.637%, -0.393%)], and -0.534% [95% CI: (-0.659%, -0.410%)], respectively.
[0280] In the FAS and PPS, the magnitude of decrease in HbA1c from baseline at W30 in all dose groups of Compound (I) was greater than that in the placebo group, and the results of various analytical methods were consistent. There was no dose-dependent trend among the dose groups of Compound (I) administered once every two weeks.
[0281] Example 4 Weight Loss Effect of Compound (I)
[0282] A long-term randomized safety and efficacy trial was conducted to evaluate the weight loss and other long-term outcomes of Compound (I) in 36 (N=36) adult obese / overweight subjects. The subject inclusion and exclusion criteria are described in Table 2.
[0283] Compound (I) injection, manufactured and provided by Gan & Lee Pharmaceutical Co., Ltd. Usage: Subcutaneous injection (equilibrate to room temperature before injection). Placebo injection: The placebo is the Compound (I) solvent excipient, but does not contain Compound (I). The remaining ingredients are identical to those of the Compound (I) injection. The placebo has the same appearance, weight, and odor as the test drug. Manufactured and provided by Gan & Lee Pharmaceutical Co., Ltd.
[0284] The subjects were randomized and administered Compound (I) injection and the same volume of placebo according to the dosing regimen in Table 8. All drugs were administered using a 3 ml disposable pen syringe. This pen syringe was the same for Compound (I) injection and placebo administration.
[0285] Injections were administered at any time of day, regardless of diet, in the thigh, abdomen, or upper arm. During the experimental period, the injections were administered on the same day of the week.
[0286] Table 8 Dose escalation regimen for compound (I) injection for weight loss
[0287] Compound (I) injection and the same volume of placebo were administered to the subjects according to the dosage regimen in Table 3. The experimental results of the efficacy and safety of the subjects are shown in Table 9.
[0288] Table 9 Efficacy and safety of compound (I) in treating overweight or obese patients in China* Note: *Efficacy was analyzed using the Full Analysis Set (FAS), and safety was analyzed using the Safety Set (SS). Both the FAS and SS included all randomized subjects who received at least one dose of study drug. All changes were from baseline to Week 35. **One subject in the Compound (I) group discontinued the study after randomization and before dosing. Data are expressed as mean (SD). Data are expressed as least square means (95% confidence intervals). Least squares mean differences were calculated from the ANCOVA model using baseline values as covariates. || Data are expressed as number of subjects (percentage). Gastrointestinal adverse events included nausea, vomiting, diarrhea, constipation, dyspepsia, and dysphagia. AE, adverse event; BMI, body mass index; CFB, change from baseline; EOT, end of treatment; IP, trial drug; TRAE, treatment-related AE; QW, once a week; Q2W, every 2 weeks.
[0289] As can be seen from Table 9, when administered once a week, the average weight loss of the subjects was 18.6% compared to the placebo. When administered once every two weeks, the average weight loss of the subjects was 13.5% compared to the placebo. There were no IP-related serious adverse events.
[0290] Example 5 Clinical Dosage Scheme
[0291] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study was conducted in Chinese adult obese / overweight subjects to evaluate the efficacy and safety of compound (I) injection in adult obese / overweight subjects.
[0292] The trial included obese / overweight adult subjects (≥18 years old) whose weight was poorly controlled by diet and exercise.
[0293] This study plans to enroll 630 adult obese / overweight subjects. Qualified subjects will be randomly assigned to Group A-24 mg group (315 cases) and Group B-48 mg group (315 cases) in a 1:1 ratio and stratified according to baseline BMI; Groups A and B will be further stratified and randomized to the Compound (I) group (252 cases) or the placebo group (63 cases) in a 4:1 ratio, with double-blind treatment within each group.
[0294] All subjects maintained a regular diet and exercise lifestyle during the study. The inclusion and exclusion criteria are described in Table 2.
[0295] The subjects were randomized and administered Compound (I) injection and the same volume of placebo according to the dosing regimen in Table 10.
[0296] Table 10 Dose escalation regimen for compound (I) injection for weight loss
[0297] The present invention has been described through the above-described embodiments. However, it should be understood that the above-described embodiments are for illustrative and illustrative purposes only and are not intended to limit the present invention to the described embodiments. Furthermore, it will be understood by those skilled in the art that the present invention is not limited to the above-described embodiments and that further variations and modifications may be made based on the teachings of the present invention, all of which fall within the scope of the present invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for treating or preventing obesity, comprising administering to a subject in need thereof about 0.25 mg to about 100 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, 2. The method according to claim 1, wherein the method comprises administering to a subject in need thereof about 0.25-100 mg, preferably about 0.5-90 mg, preferably about 1-80 mg, preferably about 1.5-80 mg, preferably about 2-80 mg, preferably about 1.5-70 mg, preferably about 2-70 mg, preferably about 3-70 mg, preferably about 1.5-60 mg, preferably about 3-60 mg, preferably about 1.5-55 mg, preferably about 3-55 mg, preferably about 1.5-48 mg, preferably about 3-48 mg, preferably about 1.5-36 mg, preferably about 3-36 mg, preferably about 1.5-30 mg, preferably about 3-30 mg, preferably about 1.5-24 mg, preferably about 3-24 mg, preferably about 1.5-18 mg, preferably about 3-18 mg, preferably about 1.5-12 mg, preferably about 3-12 mg, preferably about 4-60 mg, preferably about 5-60 mg, preferably about 7-60 mg, preferably about 8-60 mg, preferably about 9-60 mg, preferably about 10-60 mg, preferably about 11-60 mg, preferably about 12-60 mg, preferably about 6-48 mg, preferably about 7-48 mg, preferably about 9-48 mg, preferably about 12-48 mg, preferably about 15-48 mg, preferably about 24-48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof.
3. The method according to claim 1 or 2, wherein: The method comprises administering to a subject in need thereof about 0.25-100 mg, preferably about 0.5-90 mg, preferably about 1-80 mg, preferably about 1.5-80 mg, preferably about 2-80 mg, preferably about 1.5-70 mg, preferably about 2-70 mg, preferably about 3-70 mg, preferably about 3-60 mg, preferably about 1.5-55 mg, preferably about 3-55 mg, preferably about 1.5-48 mg, preferably about 3-48 mg, preferably about 1.5-36 mg, preferably about 3-36 mg, preferably about 1.5-30 mg, preferably about 3-30 The compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is preferably administered at a dose of about 1.5-24 mg, preferably about 3-24 mg, preferably about 1.5-18 mg, preferably about 3-18 mg, preferably about 1.5-12 mg, preferably about 3-12 mg, preferably about 4-60 mg, preferably about 5-60 mg, preferably about 7-60 mg, preferably about 8-60 mg, preferably about 9-60 mg, preferably about 10-60 mg, preferably about 11-60 mg, preferably about 12-60 mg, preferably about 6-48 mg, preferably about 7-48 mg, preferably about 9-48 mg, preferably about 12-48 mg, preferably about 15-48 mg, preferably about 24-48 mg.
4. The method according to any one of claims 1 to 3, wherein: The method comprises administering to a subject in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at a weekly or biweekly dose of about 0.25 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, about 70 mg, about 71 mg about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, or about 70 mg.
5. The method according to any one of claims 1 to 4, wherein: The method comprises administering a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof once a week or less, preferably once every two weeks or less.
6. The method according to any one of claims 1 to 5, wherein: The method comprises administering to a subject in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at a frequency of once a week or once every two weeks: about 0.25 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, or about 70 mg.
7. The method according to any one of claims 1 to 6, wherein: The method comprises first administering an ascending dose to a subject in need thereof at a frequency of once a week or once every two weeks during an ascending dose period, and then administering a maintenance dose at a frequency of once a week or once every two weeks during a maintenance dose period, wherein, The increasing dose period is at least two weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-31 weeks, preferably about 2-28 weeks, preferably about 2-30 weeks, preferably about 2-20 weeks, preferably the increasing dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks , about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks; The maintenance dose period is at least about two weeks, preferably about 3 weeks or more, about 4 weeks or more, about 5 weeks or more, about 6 weeks or more, about 7 weeks or more, about 8 weeks or more, about 9 weeks or more, about 10 weeks or more, about 11 weeks or more, about 12 weeks or more, about 13 weeks or more, about 14 weeks or more, about 15 weeks or more, about 16 weeks or more, about 17 weeks or more, about 18 weeks or more, about 19 weeks or more, about 20 weeks or more, about 21 weeks or more, about 22 weeks or more, about 23 weeks or more, about 24 weeks or more, about 25 weeks or more, about 26 weeks or more, about 27 weeks or more, about 28 weeks or more, about 29 weeks or more, about 30 weeks or more, about 31 weeks or more, about 32 weeks or more, about 33 weeks or more, about 34 weeks or more, about 35 weeks or more, about 36 weeks or more, about 37 weeks or more, about 38 weeks or more, about 39 weeks or more, about 40 weeks or more, about 41 weeks or more, about 42 weeks or more, The maintenance dose period is preferably about 2 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks; preferably about 2-120 weeks, preferably about 2-100 weeks, preferably about 2-80 weeks, preferably about 2-70 weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-35 weeks, preferably about 2-30 weeks, preferably about 2-20 weeks, preferably the maintenance dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks; The increasing dose is independently about 0.25 mg-70 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at each administration; preferably, the increasing dose is independently about 0.25 mg, about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 7.5 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, or about 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; The maintenance dose is about 3-70 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; preferably, the maintenance dose is about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 7.5 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, about 70 mg, about 71 mg 1mg, about 32mg, about 33mg, about 34mg, about 35mg, about 36mg, about 37mg, about 38mg, about 39mg, about 40mg, about 41mg, about 42mg, about 43mg, about 44mg, about 45mg, about 46mg, about 47mg, about 48mg, about 49mg, about 50mg, about 51mg, about 52mg, about 53mg, about 54mg, about 55mg, about 56mg, about 57mg, about 58mg, about 59mg, about 60mg, about 61mg, about 62mg, about 63mg, about 64mg, about 65mg, about 66mg, about 67mg, about 68 mg, about 69 mg, or about 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and The maintenance dose is greater than or equal to the incremental dose; Preferably: During the increasing dose period, the administration time of each different increasing dose is independently about 1 week or more, about 2 weeks or more, about 3 weeks or more, about 4 weeks or more, about 5 weeks or more, about 6 weeks or more, about 7 weeks or more, about 8 weeks or more, about 9 weeks or more, about 10 weeks or more, about 11 weeks or more, about 12 weeks or more, about 13 weeks or more, about 14 weeks or more, about 15 weeks or more, about 16 weeks or more, about 17 weeks or more, about 18 weeks or more, about 19 weeks or more, or about 20 weeks or more; preferably, during the increasing dose period, the administration time of each different increasing dose is independently about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, or about 20 weeks; Preferably: During the increasing dose period, the increasing dose is about 1.1-3 times of the previous different increasing dose, preferably about 1.1-2 times, preferably about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2.1 times, about 2.2 times, about 2.3 times, about 2.4 times, about 2.5 times, about 2.6 times, about 2.7 times, about 2.8 times, about 2.9 times or about 3 times.
8. The method according to claim 7, wherein: The increasing dose period is about 8-31 weeks, preferably about 10-31 weeks, preferably the increasing dose period is about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 30 weeks or about 31 weeks; preferably the increasing dose period is about 10 weeks, about 14 weeks, about 18 weeks, about 28 weeks, or about 31 weeks; The maintenance dose period is about 4 weeks or more, 5 weeks or more, about 12 weeks or more, about 14 weeks or more, about 16 weeks or more, about 18 weeks or more, about 20 weeks or more, about 30 weeks or more, about 40 weeks or more, about 50 weeks or more, about 60 weeks or more, about 70 weeks or more, about 80 weeks or more, or about 90 weeks or more; preferably, the maintenance dose period is about 4-20 weeks, preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, or about 20 weeks; The increasing dose is independently about 1.5 mg, about 3 mg, about 5 mg, about 6 mg, about 7 mg, about 7.5 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, at each administration. Preferably, the increasing dose is about 3 mg, about 6 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, about 24 mg, or about 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, or the increasing dose is about 1.5 mg, about 3 mg, about 5 mg, about 7 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, or about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, respectively, when each administration is independently administered; or the increasing dose is about 3 mg, about 6 mg, about 9 mg, about 12 mg, about 18 mg, about 24 mg, about 36 mg or 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, respectively, when each administration is independently administered; The maintenance dose is about 5 mg, about 12 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; and The maintenance dose is greater than or equal to the incremental dose.
9. The method according to claim 7 or 8, wherein: The method comprises first administering an increasing dose to a subject in need at a frequency of once a week or once every two weeks during an increasing dose period, and then administering a maintenance dose at a frequency of once a week or once every two weeks during a maintenance dose period, wherein, The ascending dose period is about 10 weeks, about 14 weeks, about 18 weeks, about 28 weeks, about 30 weeks, or about 31 weeks; The maintenance dose period is about 4 weeks or more, about 12 weeks or more, about 16 weeks or more, or about 20 weeks or more; preferably, the maintenance dose period is about 4 weeks, about 12 weeks, about 16 weeks, or about 20 weeks; The increasing dose is independently about 1.5 mg, about 3 mg, about 5 mg, about 6 mg, about 7 mg, about 9 mg, about 12 mg, about 15 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg or about 48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at each administration; The maintenance dose is about 5 mg, about 12 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; and The maintenance dose is greater than or equal to the incremental dose; Preferably: When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof, sequentially at a frequency of once every two weeks. about 6 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; and about 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more than about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 1 week or more; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks ... about 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 4 weeks; and about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than 16 weeks, preferably more than about 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or about 4 weeks or more; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 12 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 ... about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, for about 12 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more than 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 15 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 20 ... ) or a pharmaceutically acceptable salt, amide or ester thereof for about 4 weeks or more; about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 2 weeks or more than about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 18 mg of the compound of formula (I) once every two weeks; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 15 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 18 mg of the compound of formula (I) once every two weeks; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 15 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks; administering about 10 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ) or a pharmaceutically acceptable salt, amide or ester thereof for about 4 weeks or more; administering about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 4 weeks or more; administering about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, sequentially at a frequency of once every two weeks. about 6 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 4 weeks or more; about 24 .... ) or a pharmaceutically acceptable salt, amide or ester thereof for about 4 weeks or more; and about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 2 weeks or more than about 4 weeks; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 4 weeks or more; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 4 weeks or more; administering about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 12 ...6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 12 weeks or more; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 12 weeks or more; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for about 12 weeks or more; administering about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide about 15 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; about 15 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for about 4 weeks or more; and about 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for about 12 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 30 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof about 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than about 1 week; administering about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than about 2 weeks; administering about 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than about 4 weeks; administering about 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than about 4 weeks; administering about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks. about 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than about 4 weeks; about 15 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than about 4 weeks; about 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than about 4 weeks; .... About 24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more; and about 30 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, for about 4 weeks or more, preferably about 14 weeks or more, preferably about 16 weeks or more, preferably about 18 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks.
10. The method according to any one of claims 1 to 6 or 7 to 9, wherein: The method comprises administering to a subject in need thereof a first dose of about 0.25-5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; At least about 1 week after the first dose is administered, preferably about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks later, a second dose of about 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; preferably about 1, about 2, about 3 or about 4 weeks after the first dose is administered, a second dose of about 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; After administering the second dose for about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks, administering a third dose of about 6-24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and After administering the third dose for about 3, about 4, about 5, about 6, about 7, or about 8 weeks, a fourth dose of about 9-36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks.
11. The method according to claim 10, wherein: After administering the fourth dose for about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, a fifth dose of about 12-48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
12. The method according to claim 11, wherein: After administering the fifth dose for about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, a sixth dose of about 18-60 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
13. The method according to claim 12, wherein: After about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks of administration of the sixth dose, a seventh dose of about 24-72 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; optionally, after further administration of about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks of administration of the seventh dose, an eighth dose of about 30-84 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
14. The method according to any one of claims 10 to 13, wherein: The first dose is about 0.5-5 mg, preferably about 1-4.5 mg, preferably about 1.5-4 mg, preferably about 1.5-3.5 mg, preferably about 2-3 mg, preferably about 3 mg; and / or The second dose is about 3-7.5 mg, preferably about 3.5-7.5 mg, preferably about 4-7 mg, preferably about 4.5-6.5 mg, preferably about 5-6 mg, preferably about 6 mg; and / or The third dose is about 5-24 mg, preferably about 6-20 mg, preferably about 6-18 mg, preferably about 6-12 mg, preferably about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, or about 20 mg, preferably about 9 mg or about 12 mg; and / or The fourth dose is about 7-40 mg, preferably about 9-36 mg, preferably about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, or about 36 mg, preferably about 12 mg or about 24 mg; and / or The fifth dose is about 9-50 mg, preferably about 12-48 mg, preferably about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg or about 48 mg, preferably about 15 mg, about 18 mg or about 36 mg; and / or The sixth dose is about 12-50 mg, preferably about 18-60 mg, preferably about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, or about 60 mg, preferably about 24 mg or about 48 mg; and / or The seventh dose is about 15-75 mg, preferably about 24-72 mg, preferably about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, or about 60 mg, preferably about 30 mg, about 36 mg or about 48 mg; and / or The eighth dose is about 30-84 mg, preferably about 36-72 mg, preferably about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, about 50 mg, about 51 mg, about 52 mg, about 53 mg, about 54 mg, about 55 mg, about 56 mg, about 57 mg, about 58 mg, about 59 mg, about 60 mg, about 61 mg, about 62 mg, about 63 mg, about 64 mg, about 65 mg, about 66 mg, about 67 mg, about 68 mg, about 69 mg, about 70 mg, about 71 mg or about 72 mg, preferably about 48 mg.
15. The method according to any one of claims 1-6, 7-9 or 10-14, wherein: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 weeks or about 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and After the third dose is administered for about 4 weeks, a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks. Preferably, a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for about 20 weeks.
16. The method according to any one of claims 1-6, 7-9 or 10-14, wherein: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 weeks or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After the fourth dose is administered for about 4 weeks, a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, the fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, the fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 .... A fifth dose of about 18 mg of a compound of Formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is used for about 16 weeks.
17. The method according to claims 1-6, 7-9 or 10-14, wherein: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 weeks or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fourth dose for about 4 weeks, administering a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After the fifth dose is administered for about 4 weeks, a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, the sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, the sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for about 12 weeks.
18. The method according to claims 1-6, 7-9 or 10-14, wherein: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 weeks or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fourth dose for about 4 weeks, administering a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fifth dose for about 4 weeks, administering a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After administering the sixth dose for about 4 weeks, administering a seventh dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks, preferably administering a seventh dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; Preferably: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fourth dose for about 4 weeks, administering a fifth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fifth dose for about 4 weeks, administering a sixth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After administering the sixth dose for about 4 weeks, administer a seventh dose of about 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks; After administering the seventh dose for about 4 weeks, an eighth dose of about 48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, an eighth dose of about 48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks.
19. The method according to claims 1-6, 7-9 or 10-14, wherein: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 weeks or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for about 4 weeks, administering a fourth dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fourth dose for about 4 weeks, administering a fifth dose of about 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After the fifth dose is administered for about 4 weeks, a sixth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a sixth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, a sixth dose of about 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 12 weeks.
20. The method of claims 1-6, 7-9 or 10-14, wherein: The method comprises administering to a subject in need thereof a first dose of about 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 2 weeks or 4 weeks, administering a second dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for about 4 weeks, administering a third dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for about 4 weeks, administering a fourth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fourth dose for 4 weeks, administering a fifth dose of about 15 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After the fifth dose is administered for about 4 weeks, a sixth dose of about 24 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks. Preferably, the sixth dose of about 24 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, the sixth dose of about 24 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks for more than about 12 weeks.
21. The method according to any one of claims 1 to 6 or 7 to 9, wherein: The method comprises administering to a subject in need thereof a first dose of about 0.25-3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the first dose for about 1, about 2, about 3 or about 4 weeks, administering a second dose of about 1-5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the second dose for about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks, administering a third dose of about 3-7 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the third dose for about 2, about 3, about 4, about 5, about 6, about 7, or about 8 weeks, administering a fourth dose of about 5-9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the fourth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, administering a fifth dose of about 7-12 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or after administering the fifth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, administering a sixth dose of about 9-15 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the sixth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, administering a seventh dose of about 12-18 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the seventh dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, administering an eighth dose of about 15-24 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the eighth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, administering a ninth dose of about 18-30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the ninth dose for about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 weeks, a tenth dose of about 24-48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.
22. The method according to any one of claims 1-6, 7-9 or 21, wherein: The first dose is about 0.5-3 mg, preferably about 0.5 mg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, or about 3 mg, preferably about 1.5 mg; and / or The second dose is about 1-5 mg, preferably about 1 mg, about 2 mg, about 3 mg, about 4 mg, or about 5 mg, preferably about 3 mg; and / or The third dose is about 3-7 mg, preferably about 3 mg, about 4 mg, about 5 mg, about 6 mg, or about 7 mg, preferably about 5 mg; and / or The fourth dose is about 5-9 mg, preferably about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, preferably about 6 mg or about 7 mg; and / or The fifth dose is about 7-12 mg, preferably about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, or about 12 mg, preferably about 9 mg; and / or The sixth dose is about 9-15 mg, preferably about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg, preferably about 12 mg; and / or The seventh dose is about 12-18 mg, preferably about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, or about 18 mg, preferably about 15 mg; and / or The eighth dose is about 15-24 mg, preferably about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, or about 24 mg, preferably about 18 mg; and / or The ninth dose is about 18-30 mg, preferably about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, preferably about 24 mg; and / or The tenth dose is about 24-48 mg, preferably about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg or about 48 mg, preferably about 30 mg.
23. The method according to any one of claims 1-6, 7-9 or 21-22, wherein: The method comprises administering to a subject in need thereof a first dose of about 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for about 1 week, administering a second dose of about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week; After administering the second dose for about 2 weeks, administering a third dose of about 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week; After administering the third dose for about 4 weeks, administering a fourth dose of about 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week; After administering the fourth dose for about 4 weeks, administering a fifth dose of about 9 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fifth dose for about 4 weeks, administering a sixth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the sixth dose for about 4 weeks, administering a seventh dose of about 15 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the seventh dose for about 4 weeks, administering an eighth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the eighth dose for about 4 weeks, administering a ninth dose of about 24 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and After administering the ninth dose for about 4 weeks, a tenth dose of about 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a tenth dose of about 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than about 2 weeks, preferably more than about 4 weeks, preferably more than about 8 weeks, preferably more than about 12 weeks, preferably more than about 16 weeks, preferably more than about 20 weeks; preferably, a tenth dose of about 30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for about 4 weeks.
24. The method according to any one of claims 1 to 23, characterized in that The compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered parenterally, preferably subcutaneously.
25. The method according to any one of claims 1 to 24, characterized in that The compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered for about 10 weeks or more, preferably about 15 weeks or more, preferably about 20 weeks or more, preferably about 25 weeks or more, preferably about 30 weeks or more, preferably about 35 weeks or more, preferably about 12 months or more, preferably about 16 months or more, preferably about 18 months or more, preferably about 24 months or more, preferably about 28 months or more, preferably about 29 months or more, preferably about 30 months or more.
26. The method according to any one of claims 1 to 25, characterized in that The subject's BMI is ≥ 24 kg / m 2 , preferably BMI ≥ 25 kg / m 2 , preferably BMI ≥ 26 kg / m 2 ; Preferred: The subject also has at least one of the following symptoms: 1) Patients with one or more of the following: prediabetes, hypertension, dyslipidemia, and fatty liver; 2) Combined with weight-bearing joint pain; and 3) Obesity causes breathing difficulties or obstructive sleep apnea syndrome.
27. The method according to any one of claims 1 to 26, wherein the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients.
28. The method according to claim 27, wherein the pharmaceutical composition comprises: about 3 mg / ml, about 6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 24 mg / ml, about 36 mg / ml, or about 48 mg / ml of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; about 5 mg / ml, about 6 mg / ml, about 7 mg / ml, about 8 mg / ml, about 9 mg / ml or about 10 mg / ml of NaCl, preferably about 7 mg / ml of NaCl; About 1 mM, 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, 9 mM or about 10 mM citric acid; about 1.42 mg / ml, about 1.5 mg / ml, about 2 mg / ml, about 2.5 mg / ml, about 3 mg / ml, about 3.5 mg / ml, about 4 mg / ml, or about 4.5 mg / ml of a Na2HPO4 solution, preferably about 1.42 mg / ml of Na2HPO4; and The pH of the pharmaceutical composition is about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, or about 8.2, preferably about 7.
3.
29. The method according to any one of claims 1 to 28, characterized in that The subject can achieve a weight loss of about 5% or more, preferably about 10%-60%, preferably about 10%-50%, preferably about 10%-40%, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 10.16%, about 11%, about 11.15%, about 12%, about 12.23%, about 13%, about 13.22%, about 13.26%, about 13.5%, about 14%, about 14.25%, about 15%, about 16%, about 16.3%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about about 16.79%, about 17%, about 17.29%, about 17.78%, about 18%, about 18.6%, about 19%, or about 20%; preferably, the subject can achieve a weight loss of about 10% or more, preferably about 10%-30%, preferably about 10%-20% after about 10 weeks, about 20 weeks, about 25 weeks, about 30 weeks, or about 35 weeks of administration of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof. 5%, preferably about 10%, about 10.16%, about 11%, about 11.15%, about 12%, about 12.23%, about 13%, about 13.22%, about 13.26%, about 13.5%, about 14%, about 14.25%, about 15%, about 16%, about 16.3%, about 16.79%, about 17%, about 17.29%, about 17.78%, about 18%, about 18.6%, about 19%, or about 20%.
30. The method according to any one of claims 1 to 29, characterized in that The subject can achieve a weight loss of about 10% or more, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 11%, about 12%, about 13%, about 13.5%, about 14%, about 15%, about 16%, about 17%, about 18%, about 18.6%, about 19%, or about 20% after administering the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester; preferably, the subject can achieve a weight loss of about 10% or more, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 11%, about 12%, about 13%, about 13.5%, about 14%, about 15%, about 16%, about 17%, about 18%, about 18.6%, about 19%, or about 20% after administering the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester Pharmaceutically acceptable salts, amides or esters can achieve a weight loss of about 10% or more, preferably about 10%-30%, preferably about 10%-25%, preferably about 10%, about 11%, about 12%, about 13%, about 13.5%, about 14%, about 15%, about 16%, about 17%, about 18%, about 18.6%, about 19%, or about 20% after about 10 weeks, about 20 weeks, about 25 weeks, about 30 weeks or about 35 weeks.
31. The method according to claim 15, characterized in that When a fourth dose of about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 20 weeks, the average body weight of the subjects is reduced by more than about 11.15% from the baseline.
32. The method according to claim 16, characterized in that When the fifth dose of about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 16 weeks, the average body weight of the subjects is reduced by more than about 13.22% from the baseline.
33. The method according to claim 17, characterized in that When the sixth dose of about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 12 weeks, the average body weight of the subjects is reduced by more than about 14.25% from the baseline.
34. The method according to claim 18, characterized in that When the seventh dose of about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than about 8 weeks, the average body weight of the subjects is reduced by more than about 17.29% from the baseline.
35. The method according to claim 17, characterized in that When the sixth dose of about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for more than about 12 weeks, the average body weight of the subjects is reduced by more than about 17.78% from the baseline.
